araag2/HINT huggingface dataset:
Clinical trial NCT00253903 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders, insomnia
ICD codes: Y93.E9, Y93.H9, F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: eplivanserin (sr46349), placebo
SMILES: CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Out patients

          -  Each patient must have primary insomnia in accordance with DSM-IV-TR-Axis I criteria

          -  Based on patient's information, the patient has spent at least 6.5 hours and not more
             than 9.0 hours, in bed, each night, over the preceding two weeks.

          -  Based on patient's information, the patient must complain of at least one hour of
             wakefulness after sleep onset for at least 3 nights per week over the preceding month

          -  Patient must report impact daytime functioning associated with sleep maintenance
             insomnia as measured by question 3 of Insomnia Severity Index at screening visit and
             randomization visit.

        Exclusion Criteria:

          -  Females who are lactating or pregnant

          -  Woman of childbearing potential with a positive serum beta human chorionic
             gonadotropin pregnancy test at screening and not using an acceptable form of
             contraception

          -  Patients presenting with acute or chronic pain resulting in insomnia

          -  Patients with history of epilepsy or seizures

          -  Consumption of xanthine containing beverage (i.e. tea, coffee, or cola) comprising
             more than 5 glasses/day

          -  Evidence of any clinically significant, severe, or unstable acute or chronically
             progressive medical or surgical disorder which may affect patient safety

          -  BMI >32

          -  Acute or chronic pain resulting in insomnia

          -  Patients with current psychiatric disorders according to DSM-IV-TR criteria, mental
             retardation, or dementia

          -  Clinically significant and abnormal EKG (QTc interval >500 msec)

          -  Positive for hepatitis B or C

          -  Serious head injury or stroke within 1 year

          -  Use of OTC medications such as valerian root, kava, melatonin, St. John's Wort, or
             alluna; prescription sleep medications or anxiolytics within 1 week or 5 half-lives

          -  Participation in another trial within two month before the screening visit

          -  Use of any substance with psychotropic effects or properties known to affect
             sleep/wake

          -  Unable to complete the study questionnaires

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  History of:

               -  Primary hypersomnia

               -  Narcolepsy

               -  Breathing-related sleep disorder (such as sleep apnea)

               -  Circadian rhythm sleep disorder

               -  Parasomnia (somnambulism)

               -  Dyssomnia (such as periodic leg movements)
Clinical trial NCT01212471 (phase 3, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: bromfenac ophthalmic solution a, bromfenac ophthalmic solution b, placebo comparator
SMILES: NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1, NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Be of either gender and any race 18 years or older

        Exclusion Criteria:

          -  Have a local or systemic disease that could interfere with the assessment of safety or
             efficacy or that is likely to result in early discontinuation from the study
Clinical trial NCT00434161 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: palifermin before only, placebo, palifermin before and after
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Multiple myeloma (MM) subjects scheduled to receive high-dose Melphalan in a one day
             schedule followed by autologous peripheral blood progenitor cell (PBSCT)

          -  Body Mass Index (BMI) ≤ 35

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, or an ECOG status of
             3 if the reason for a status of 3 is exclusively due to MM (e.g. pathological
             fracture)

          -  Functional hematopoietic, hepato-renal and pulmonary systems

          -  Subjects at minimum with a baseline best corrected visual acuity (BCVA) of 20/40,
             (6/12 or 0.5 on the decimal scale) or better using the ETDRS chart in one eye

          -  Subject at minimum with one eye with a natural, intact lens

          -  Subject who has a LOCS III score at baseline of P < 1.0, C < 2.0 and NO < 2.0 in at
             least one eye

          -  Women in child bearing potential must have a negative pregnancy test

        Exclusion Criteria:

          -  Presence or history of any other malignancy (other than curatively treated basal cell
             or squamous cell carcinoma of the skin, in situ cervical carcinoma, or other
             surgically cured malignancy, without evidence of disease for > 3 years

          -  Prior autologous or allogeneic transplants

          -  Prior treatment with palifermin, or other fibroblast or keratinocyte growth factors

          -  Receiving dialysis

          -  History of cataract surgery in both eyes

          -  Incapable of being responsive to mydriatic agents

          -  History of other ocular disease (e.g., macular degeneration, glaucoma, corneal
             disease) that would make assessment of visual status difficult

          -  Subject is scheduled to undergo cataract surgery

          -  Subject with any disease, that in the opinion of the ophthalmologist, could adversely
             effect the subject's vision during the course of the study

          -  Currently active oral mucositis infection

          -  Positive for HIV, hepatitis B or C

          -  Subject is unable or unwilling to follow with study procedures

          -  Subject is pregnant or is breast feeding

          -  Subject has not agreed to use adequate contraceptive precautions
Clinical trial NCT00413010 (phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male and female subjects with primary DSM-IV diagnosis of GAD, as confirmed by
             the MINI structured interview.

          -  Historical failure to respond optimally to a GAD treatment

        Exclusion Criteria:

          -  Current primary DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th
             edition) diagnosis of major depressive disorder with or without seasonal pattern,
             dysthmic disorder, depressive disorder NOS (not otherwise specified), social phobia,
             panic disorder with or without agoraphobia, post traumatic stress disorder,
             dissociative disorder, borderline personality disorder, obsessive-compulsive disorder,
             antisocial personality disorder, as defined in the DSM-IV TR (Diagnostic and
             Statistical Manual of Mental Disorders 4th edition, Text Revision).

          -  Past and/or current DSM-IV diagnosis of schizophrenia, schizoaffective disorder, other
             psychotic disorders, bipolar disorders (I or II), factitious disorder or cognitive
             disorder (including delirium, dementia, and amnestic disorder).
Clinical trial NCT00347412 (phase 3, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel and carboplatin, nov-002 injection in combination with carboplatin vs. paclitaxel and carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Stage IIIb with malignant pleural or pericardial effusion or Stage IV
             (American Joint Committee on Cancer [AJCC]) NSCLC

          -  ECOG performance score of 0 or 1

          -  Adequate bone marrow, hepatic, and renal function

          -  New York Heart Association (NYHA) score 1-2

          -  Life expectancy of at least 12 weeks

          -  Women of child-bearing potential and men whose partners are of child-bearing potential
             must be willing to use an acceptable method of birth control during trial
             participation or are surgically sterile or women who are post-menopausal (defined as
             not having a menstrual cycle for greater than two years).

          -  The patient or patient's legal representative has the ability to understand the
             requirements of the trial, has provided written informed consent, and agrees to abide
             by the trial restrictions and to return for the required assessments.

          -  The patient must be able to self administer daily subcutaneous injections or his/her
             caregiver must be able to administer daily subcutaneous injections.

        Exclusion Criteria:

          -  Prior chemotherapy for advanced NSCLC or the patient has received prior neoadjuvant or
             adjuvant chemotherapy for NSCLC in the year prior to the date of randomization

          -  Patients with central nervous system (CNS) metastases

          -  Any systemic disease precluding chemotherapy

          -  Chronic use of systemic corticosteroids in pharmacological doses

          -  Known or history of HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Contraindication to treatment with paclitaxel or carboplatin or any of the components
             of NOV-002

          -  Any known preexisting medical condition, including substance abuse, that could
             interfere with the patient's participation in and completion of the protocol

          -  Have received any investigational drug, defined as a drug for which there is no Food
             and Drug Administration (FDA) approved indication, within the 30 days prior to
             randomization

          -  Pregnant female or nursing mother
Clinical trial NCT00049452 (phase 3, status: completed)
Conditions: breast cancer, osteoporosis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of localized breast cancer

               -  Stage I or II (T1-3, N0-2, M0)

          -  Planned adjuvant chemotherapy (after surgery) of at least 6 months in duration

          -  Hormone receptor status:

               -  Estrogen receptor and progesterone receptor status known

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 50

        Sex

          -  Female

        Menopausal status

          -  Premenopausal or perimenopausal

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Creatinine less than 2 mg/dL

        Other

          -  No T score of less than 2.0 on bone mineral density (BMD)

          -  No fragility fracture

          -  No lumbar spine anatomy that would preclude accurate BMD measurement of a minimum of 3
             lumbar vertebrae

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  At least 1 month since prior calcitonin

          -  At least 12 months since prior bisphosphonates given for more than 1 month duration

          -  No concurrent fluoride therapy (10 mg/day or more)

          -  No concurrent enrollment in another experimental drug study
Clinical trial NCT00307905 (phase 3, status: withdrawn)
Conditions: pain, fracture of neck of femur
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: traumeel s, placebo remedy
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    anticipation of inadequate recruitment according to current format.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients of either sex undergoing surgical correction of unilateral fracture of neck
             of hip.

          -  Age over 18 years.

          -  Signature upon informed consent form

        Exclusion Criteria:

          -  Participation in another clinical trial within 4 weeks prior to enrollment.

          -  Refused to give verbal consent to the telephone interviews

          -  Impossibility to be reached during the 14-17 days post operative

          -  Inability to comply with the study protocol for any other reason

          -  Previous major surgical procedure on ipsilateral hip.

          -  Current use of analgesics for any other reason.

          -  A history of chronic pain syndrome.

          -  Abused legal or illicit drug use.

          -  Hypersensitivity to botanicals of the Compositae family

          -  Known sensitivity to paracetamol, codeine or tramadol.
Clinical trial NCT01572740 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, placebo, insulin
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Current insulin therapy (basal insulin, premixed insulin or basal-bolus regimen) in
             addition to diet and exercise therapy for at least 12 weeks prior to trial start.
             Their therapy is stable and fluctuation of total daily insulin dose is within
             plus/minus 20% for at least 12 weeks prior to trial start and current total daily
             insulin dose equal to or greater than 10 (I)U/day

          -  Glycosylated haemoglobin (HbA1c) between 7.5 and 11.0% (both inclusive)

          -  Body Mass Index (BMI) below 45.0 kg/m^2

        Exclusion Criteria:

          -  Anticipated change in concomitant medication known to interfere significantly with
             glucose metabolism, such as, but not limited to systemic corticosteroids,
             beta-antagonists or monoamine oxidase (MAO) inhibitors

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode during last
             12 months) or hypoglycaemic unawareness as judged by the investigator or
             hospitalisation for diabetic ketoacidosis during the previous 6 months

          -  Known proliferative retinopathy or maculopathy requiring treatment according to the
             investigator

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior
             to screening

          -  Treatment with any oral antidiabetic drugs (OADs) within 12 weeks prior to screening
Clinical trial NCT00411385 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: albumin interferon alfa-2b, peginterferon alfa-2a, ribavirin
SMILES: CC1=CC(O)=CC(C)=C1Cl, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of chronic hepatitis C.

          -  Liver biopsy performed within 2 years of Day 0 or during screening.

          -  Infected with hepatitis C virus genotype 2/3.

          -  Interferon alfa treatment naïve (ie, have never been treated with an interferon
             product).

          -  Subjects are eligible to enter the study if they (or their partners) are not pregnant
             or nursing, are sterile, or of non childbearing potential, or are willing to practice
             abstinence or use appropriate birth control methods during the study and for 7 months
             after the last dose of ribavirin.

          -  Have compensated liver disease.

        Key Exclusion Criteria:

          -  Decompensated liver disease including those subjects with a past history or presence
             of ascites, bleeding varices or hepatic encephalopathy.

          -  History of moderate, severe or uncontrolled psychiatric disease, especially
             depression, including a history of hospitalization or prior suicidal attempt.

          -  Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen
             (HBsAG).

          -  Clinical diagnosis of other causes of chronic liver disease including but not limited
             to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver
             disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.

          -  A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory
             bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).

          -  Active seizure disorder within the last 2 years.

          -  Organ transplant other than cornea and hair transplant.

          -  Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).

          -  Cancer within the last 5 years(with the exception of adequately treated basal cell
             carcinoma of the skin or in situ carcinoma of the uterine cervix).

          -  Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone
             treatment program may be enrolled in the study.

          -  Received any experimental agent within 28 days prior to Day 0.
Clinical trial NCT00384605 (phase 3, status: terminated)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: taranabant, placebo
SMILES: C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the overall profile does not support development for obesity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years of age or older, with Body Mass Index (BMI) between 30 kg/m2
             and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43 kg/m2, inclusive, for those with
             obesity-related comorbidities). Obesity-related comorbidities associated with a BMI of
             27 kg/m2 or higher include hypertension, dyslipidemia or sleep apnea

          -  Stable weight (+/-3 kg) for at least 3 months prior to study start

        Exclusion Criteria:

          -  History of diabetes mellitis, major psychiatric disorder, significant cardiovascular
             disease, stroke, TIA, neurological disorder, non-febrile seizures

          -  Screening systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg
Clinical trial NCT01284517 (phase 3, status: completed)
Conditions: bipolar depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: lurasidone, placebo
SMILES: [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Provide written informed consent and is 18 to 75 years of age inclusive.

          2. Meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4
             weeks and less than 12 months) without psychotic features.

          3. Has a lifetime history of at least one bipolar manic or mixed manic episode.

          4. Currently being treated with lithium or divalproex or willing to begin treatment with
             lithium or divalproex.

          5. Not pregnant or nursing and is not planning pregnancy within the projected duration of
             the study.

          6. Females of reproductive potential agree to remain abstinent or use adequate and
             reliable contraception throughout the study and for at least 30 days after

          7. Good physical health on the basis of medical history, physical examination, and
             laboratory screening.

        Exclusion Criteria:

          1. Subject is considered by the investigator to be at imminent risk of suicide or injury
             to self, others, or property.

          2. Any chronic organic disease of the CNS (other than Bipolar I Disorder).

          3. Hospitalization for a manic or mixed episode within the past two months.

          4. Used investigational compound within past 6 months.

          5. Clinically significant history of alcohol or substance abuse within the past 3 months
             or alcohol or substance dependence within the past 12 months.
Clinical trial NCT00141219 (phase 3, status: completed)
Conditions: diabetic neuropathies, neuralgia
ICD codes: G60.8, G50.0, M54.81, B02.22, M79.2
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of peripheral neuropathic pain syndrome, including diabetic peripheral
             neuropathy (DPN), postherpetic neuralgia (PHN), or post-traumatic neuropathic pain
             (including post-surgical), confirmed by a qualified pain specialist.

          -  Subjects must have completed at least 4 daily pain diaries during the 7 days prior to
             Visit 2 and have an average pain score of ≥4 over the 7 days prior to Visit 2
             (randomization).

        Exclusion Criteria:

          -  Neurologic disorders unrelated to DPN, PHN, or post-traumatic neuropathic pain
             (including post-surgical), that may confuse or confound the assessment of neuropathic
             pain.

          -  Presence of any severe pain associated with conditions other than DPN, PHN, or
             post-traumatic neuropathic pain (including post-surgical) that may confound the
             assessment or self evaluation of the pain due to DPN, PHN, or post-traumatic
             neuropathic pain (including post-surgical).

          -  Creatinine clearance < 30 mL/min (estimated from serum creatinine, body weight, age,
             and sex using the Cockcroft and Gault equation in Appendix E). Maximum dose for
             subjects with creatinine clearance of 30 to 60 mL/min is 300 mg/day